Chanelle Pharma announces successful compilation of new Bisoprolol tablets dossier.
Chanelle Pharma is pleased to announce that we have successfully finalised a new dossier for Bisoprolol (1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, and 10mg).
A β-Blocker medication, Bisoprolol is considered a key therapeutic option for people with Heart failure, Hypertension, and Angina. Chanelle previously launched Bisoprolol in 2009 and since then, has been supplying the product worldwide. The company estimates in 2021, over 1 million people were treated with Bisoprolol produced by Chanelle Pharma.
The EU-CTD dossier includes a new clinical study to support applications to regulatory authorities worldwide for market approval.
With an increasingly aging population, sedentary lifestyles and rising obesity rates, together with an improvement in terms of diagnosis and treatment by healthcare professionals, Chanelle Pharma anticipate significant growth in the demand for Bisoprolol globally.
The product is manufactured from our facilities in Loughrea, Ireland.
If you are interested in this product, please reach out to our business development team to discuss out-licensing or distribution options.
Email: businessdevelopment@chanellegroup.ie for more information.
